Roche says Tecentriq, chemo cut risk of death in type of lung cancer

ZURICH (Reuters) - Roche's immunotherapy Tecentriq plus chemotherapy cut the risk of disease worsening or death in advanced squamous lung cancer, but it did not yet show an overall survival benefit in this tough-to-treat disease, the Swiss drugmaker said Tuesday.